FGFR1 amplification	Hormone Receptor Positive Breast Cancer	FGFR1 amplification	Hormone Receptor Positive Breast Cancer	letrozole Resistant: B - Late Trials letrozole Resistant : B	letrozole Resistant: B - Late Trials letrozole Resistant : B
FGFR1 amplification	Lung Non-Small Cell Squamous Cancer	FGFR1 amplification	Lung Non-Small Cell Squamous Cancer	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR1 amplification	Breast Cancer	FGFR1 amplification	Breast Cancer	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2
FGFR1 amplification	Gastric Cancer	FGFR1 amplification	Gastric Cancer	ABSK091 Sensitive: C2 – Inclusion Criteria ABSK091 Sensitive : C2	ABSK091 Sensitive: C2 – Inclusion Criteria ABSK091 Sensitive : C2
FGFR1 amplification	Bladder Cancer	FGFR1 amplification	Bladder Cancer	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR1 amplification	Breast Cancer	FGFR1 amplification	Breast Cancer	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR1 amplification	Breast Cancer	FGFR1 amplification	Breast Cancer	TKI258 Sensitive: C2 – Inclusion Criteria TKI258 Sensitive : C2	TKI258 Sensitive: C2 – Inclusion Criteria TKI258 Sensitive : C2
FGFR1 amplification	Breast Cancer	FGFR1 amplification	Breast Cancer	ABSK091 Sensitive: C2 – Inclusion Criteria ABSK091 Sensitive : C2	ABSK091 Sensitive: C2 – Inclusion Criteria ABSK091 Sensitive : C2
FGFR1 amplification	Breast Cancer	FGFR1 amplification	Breast Cancer	Aromatase inhibitor Resistant: C3 – Early Trials Aromatase inhibitor Resistant : C3	Aromatase inhibitor Resistant: C3 – Early Trials Aromatase inhibitor Resistant : C3
FGFR1 amplification	HER2 Negative Breast Cancer	FGFR1 amplification	HER2 Negative Breast Cancer	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3
FGFR1 amplification	Breast Cancer	FGFR1 amplification	Breast Cancer	Debio 1347 Resistant: C3 – Early Trials Debio 1347 Resistant : C3	Debio 1347 Resistant: C3 – Early Trials Debio 1347 Resistant : C3
FGFR1 amplification	Lung Non-Small Cell Squamous Cancer	FGFR1 amplification	Lung Non-Small Cell Squamous Cancer	TKI258 Sensitive: C3 – Early Trials TKI258 Sensitive : C3	TKI258 Sensitive: C3 – Early Trials TKI258 Sensitive : C3
FGFR1 amplification	HER2 Positive Breast Cancer	FGFR1 amplification	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials trastuzumab + pertuzumab Sensitive : C3	trastuzumab + pertuzumab Sensitive: C3 – Early Trials trastuzumab + pertuzumab Sensitive : C3
FGFR1 amplification	HER2 Positive Breast Cancer	FGFR1 amplification	HER2 Positive Breast Cancer	trastuzumab Sensitive: C3 – Early Trials trastuzumab Sensitive : C3	trastuzumab Sensitive: C3 – Early Trials trastuzumab Sensitive : C3
FGFR1 amplification	Hormone Receptor Positive Breast Cancer	FGFR1 amplification	Hormone Receptor Positive Breast Cancer	palbociclib + BAY 1163877 Sensitive: C3 – Early Trials palbociclib + BAY 1163877 Sensitive : C3	palbociclib + BAY 1163877 Sensitive: C3 – Early Trials palbociclib + BAY 1163877 Sensitive : C3
FGFR1 amplification	HER2 Negative Breast Cancer	FGFR1 amplification	HER2 Negative Breast Cancer	pazopanib Sensitive: C4 – Case Studies pazopanib Sensitive : C4	pazopanib Sensitive: C4 – Case Studies pazopanib Sensitive : C4
FGFR1 amplification	Non Small Cell Lung Cancer	FGFR1 amplification	Non Small Cell Lung Cancer	M6123 Sensitive: D – Preclinical M6123 Sensitive : D	M6123 Sensitive: D – Preclinical M6123 Sensitive : D
FGFR1 amplification	Estrogen Receptor Positive Breast Cancer	FGFR1 amplification	Estrogen Receptor Positive Breast Cancer	ponatinib Sensitive: D – Preclinical ponatinib Sensitive : D	ponatinib Sensitive: D – Preclinical ponatinib Sensitive : D
FGFR1 amplification	Lung Cancer	FGFR1 amplification	Lung Cancer	futibatinib Sensitive: D – Preclinical futibatinib Sensitive : D	futibatinib Sensitive: D – Preclinical futibatinib Sensitive : D
FGFR1 amplification	Colorectal Cancer	FGFR1 amplification	Colorectal Cancer	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D
FGFR1 amplification	Small Cell Lung Cancer	FGFR1 amplification	Small Cell Lung Cancer	futibatinib + TAS-117 Sensitive: D – Preclinical futibatinib + TAS-117 Sensitive : D	futibatinib + TAS-117 Sensitive: D – Preclinical futibatinib + TAS-117 Sensitive : D
FGFR1 amplification	Non Small Cell Lung Cancer	FGFR1 amplification	Non Small Cell Lung Cancer	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D
FGFR1 amplification	Lung Cancer	FGFR1 amplification	Lung Cancer	ponatinib Sensitive: D – Preclinical ponatinib Sensitive : D	ponatinib Sensitive: D – Preclinical ponatinib Sensitive : D
FGFR1 amplification	Lung Non-Small Cell Squamous Cancer	FGFR1 amplification	Lung Non-Small Cell Squamous Cancer	ABSK091 Sensitive: D – Preclinical ABSK091 Sensitive : D	ABSK091 Sensitive: D – Preclinical ABSK091 Sensitive : D
FGFR1 amplification	Breast Cancer	FGFR1 amplification	Breast Cancer	afimoxifene Resistant: D – Preclinical afimoxifene Resistant : D	afimoxifene Resistant: D – Preclinical afimoxifene Resistant : D
FGFR1 amplification	Breast Cancer	FGFR1 amplification	Breast Cancer	PD173074 Sensitive: D – Preclinical PD173074 Sensitive : D	PD173074 Sensitive: D – Preclinical PD173074 Sensitive : D
FGFR1 amplification	Gastric Cancer	FGFR1 amplification	Gastric Cancer	ponatinib Sensitive: D – Preclinical ponatinib Sensitive : D	ponatinib Sensitive: D – Preclinical ponatinib Sensitive : D
FGFR1 amplification	Breast Cancer	FGFR1 amplification	Breast Cancer	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D
FGFR1 amplification	Lung Cancer	FGFR1 amplification	Lung Cancer	ABSK091 + NBL-001 + BI2536 Sensitive: D – Preclinical ABSK091 + NBL-001 + BI2536 Sensitive : D	ABSK091 + NBL-001 + BI2536 Sensitive: D – Preclinical ABSK091 + NBL-001 + BI2536 Sensitive : D
FGFR1 amplification	Lung Cancer	FGFR1 amplification	Lung Cancer	NBL-001 + BI2536 Sensitive: D – Preclinical NBL-001 + BI2536 Sensitive : D	NBL-001 + BI2536 Sensitive: D – Preclinical NBL-001 + BI2536 Sensitive : D

FGFR1 amplification

Associations